Introduction & objectives: Hemosiderosis Caused by chronic transfusion and higher gastrointestinal absorption of iron in thalassemic patients leads to cardiac and endocrine disorders among which is the most common cause of death in these patients that is CHF. These have led to frequent use of various chelators such as deferoxamine to decrease the disorders mentioned above; Bone dysplasia have been frequently reported as an adverse effect of deferoxamine.
In order to early diagnosis of bone dysplasia caused by deferoxamine several radiographic studies are used such as boonX-rays; Bone dysplasia in major thalassemic patients using comparison of wrist and knee X-rays in Bu Ali Hospital. Ardebil. Iran.
Methods & Materials: Int this descriptive – analytic- cross – sectional study 47 major thalassemic patients who were regulary receiving transfusions and deferoxamine doses underwent wrist and knee X_rays while simultaneously their ferritin levels were measured. The patients then divided into 2 groups; with dysplasia & without dysplasia. Then the 2 groups were compared in ferms of the age of initiation of treatment with desferal duration of treatment with deferoxamine, average dose of received deferoxamine and ferritin levels at the time of X-rays.
Data were analyzed by SPSS software and uU-Mann-Whitney and wilcoxon signed ranks tests and p< 0.05 were considered significant.
Results: Our results showed that 31 out 47 major thalassemic patients (66%) had bone dysplasias.
Furtheremore, wrist X-rays P <0.001 had diagnostic superiority over knee X-rays.
Furthermore, no statistical relationships were found between presence of dysplasia and the age of initiation of deferoxamine treatment, duration of deferoxamine treatment, average dose of received deferoxamine, and ferritin levels.
Discussion & Conclusion: Regarding the significant difference X-rays, wrist X-ray is proposed as the preferred imaging study for diagnosis of dysplasia.
Furthermore, there were no relationships between presence of dysplasia and the age of initiation of deferoxamine, duration of treatment with deferoxamine, average dose of received deferroxamine, and ferritin levels
